On September 22, 2025, GENFIT SA (NASDAQ:GNFT) reported its earnings, revealing an EPS of -$0.24, which was significantly below the expected $1.19. The company's revenue was approximately $40.3 million, falling short of the estimated $114.7 million. GENFIT is a biopharmaceutical company focusing on rare liver diseases, with its financial results reflecting challenges in meeting market expectations.
GENFIT's financial results for the first half of 2025 show cash and cash equivalents of €107.5 million as of June 30, 2025. This figure does not include a €26.5 million milestone payment received in July 2025, following the approval of Iqirvo in three major European countries. Despite the earnings miss, this cash position provides a solid foundation for future operations.
The company's revenues for the first half of 2025 were €33.5 million, supported by the milestone payment. Iqirvo's strong sales trajectory in primary biliary cholangitis (PBC) was noted, especially after a key competitor exited the U.S. market in September. This development could positively impact future revenue streams for GENFIT.
GENFIT's strategic decisions, such as discontinuing the VS-01 program, extend its cash runway beyond 2028. This provides flexibility for future business initiatives. The company is advancing its pipeline, with Phase 1b data for GNS561 in cholangiocarcinoma expected by the end of 2025, alongside safety data for G1090N in ACLF.
Financial metrics reveal a price-to-sales ratio is 2.53, and the enterprise value to sales ratio is 2.25, reflecting the company's market valuation. The debt-to-equity ratio of 0.90 shows a balanced use of debt and equity, while a current ratio of 1.23 suggests reasonable liquidity.
